DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients

Khaldon Bodoor, Yazan Haddad, Asem Alkhateeb, Abdullah Al-Abbadi, Mohammad Dowairi, Ahmad Magableh, Nazzal Bsoul, Abdulhameed Ghabkari

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aberrant DNA methylation of tumor suppressor genes has been reported in all major types of leukemia with potential involvement in the inactivation of regulatory cell cycle and apoptosis genes. However, most of the previous reports did not show the extent of concurrent methylation of multiple genes in the four leukemia types. Here, we analyzed six key genes (p14, p15, p16, p53, DAPK and TMS1) for DNA methylation using methylation specific PCR to analyze peripheral blood of 78 leukemia patients (24 CML, 25 CLL, 12 AML, and 17 ALL) and 24 healthy volunteers. In CML, methylation was detected for p15 (11%), p16 (9%), p53 (23%) and DAPK (23%), in CLL, p14 (25%), p15 (19%), p16 (12%), p53 (17%) and DAPK (36%), in AML, p14 (8%), p15 (45%), p53 (9%) and DAPK (17%) and in ALL, p15 (14%), p16 (8%), and p53 (8%). This study highlighted an essential role of DAPK methylation in chronic leukemia in contrast to p15 methylation in the acute cases, whereas TMS1 hypermethylation was absent in all cases. Furthermore, hypermethylation of multiple genes per patient was observed, with obvious selectiveness in the 9p21 chromosomal region genes (p14, p15 and p16). Interestingly, methylation of p15 increased the risk of methylation in p53, and vice versa, by five folds (p=0.03) indicating possible synergistic epigenetic disruption of different phases of the cell cycle or between the cell cycle and apoptosis. The investigation of multiple relationships between methylated genes might shed light on tumor specific inactivation of the cell cycle and apoptotic pathways.

Original languageEnglish
Pages (from-to)75-84
Number of pages10
JournalAsian Pacific Journal of Cancer Prevention
Volume15
Issue number1
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Methylation
Cell Cycle
Leukemia
DNA
Genes
DNA Methylation
Apoptosis
cdc Genes
Regulator Genes
Tumor Suppressor Genes
Epigenomics
Healthy Volunteers
Polymerase Chain Reaction
Neoplasms

Keywords

  • Acute leukemia
  • Chronic leukemia
  • DAPK
  • DNA methylation
  • p14
  • p15
  • p16
  • p53
  • TMS1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients. / Bodoor, Khaldon; Haddad, Yazan; Alkhateeb, Asem; Al-Abbadi, Abdullah; Dowairi, Mohammad; Magableh, Ahmad; Bsoul, Nazzal; Ghabkari, Abdulhameed.

In: Asian Pacific Journal of Cancer Prevention, Vol. 15, No. 1, 2014, p. 75-84.

Research output: Contribution to journalArticle

Bodoor, Khaldon ; Haddad, Yazan ; Alkhateeb, Asem ; Al-Abbadi, Abdullah ; Dowairi, Mohammad ; Magableh, Ahmad ; Bsoul, Nazzal ; Ghabkari, Abdulhameed. / DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients. In: Asian Pacific Journal of Cancer Prevention. 2014 ; Vol. 15, No. 1. pp. 75-84.
@article{adcda1795cb24adc93aa43e2c17a6950,
title = "DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients",
abstract = "Aberrant DNA methylation of tumor suppressor genes has been reported in all major types of leukemia with potential involvement in the inactivation of regulatory cell cycle and apoptosis genes. However, most of the previous reports did not show the extent of concurrent methylation of multiple genes in the four leukemia types. Here, we analyzed six key genes (p14, p15, p16, p53, DAPK and TMS1) for DNA methylation using methylation specific PCR to analyze peripheral blood of 78 leukemia patients (24 CML, 25 CLL, 12 AML, and 17 ALL) and 24 healthy volunteers. In CML, methylation was detected for p15 (11{\%}), p16 (9{\%}), p53 (23{\%}) and DAPK (23{\%}), in CLL, p14 (25{\%}), p15 (19{\%}), p16 (12{\%}), p53 (17{\%}) and DAPK (36{\%}), in AML, p14 (8{\%}), p15 (45{\%}), p53 (9{\%}) and DAPK (17{\%}) and in ALL, p15 (14{\%}), p16 (8{\%}), and p53 (8{\%}). This study highlighted an essential role of DAPK methylation in chronic leukemia in contrast to p15 methylation in the acute cases, whereas TMS1 hypermethylation was absent in all cases. Furthermore, hypermethylation of multiple genes per patient was observed, with obvious selectiveness in the 9p21 chromosomal region genes (p14, p15 and p16). Interestingly, methylation of p15 increased the risk of methylation in p53, and vice versa, by five folds (p=0.03) indicating possible synergistic epigenetic disruption of different phases of the cell cycle or between the cell cycle and apoptosis. The investigation of multiple relationships between methylated genes might shed light on tumor specific inactivation of the cell cycle and apoptotic pathways.",
keywords = "Acute leukemia, Chronic leukemia, DAPK, DNA methylation, p14, p15, p16, p53, TMS1",
author = "Khaldon Bodoor and Yazan Haddad and Asem Alkhateeb and Abdullah Al-Abbadi and Mohammad Dowairi and Ahmad Magableh and Nazzal Bsoul and Abdulhameed Ghabkari",
year = "2014",
doi = "10.7314/APJCP.2014.15.1.75",
language = "English",
volume = "15",
pages = "75--84",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "1",

}

TY - JOUR

T1 - DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients

AU - Bodoor, Khaldon

AU - Haddad, Yazan

AU - Alkhateeb, Asem

AU - Al-Abbadi, Abdullah

AU - Dowairi, Mohammad

AU - Magableh, Ahmad

AU - Bsoul, Nazzal

AU - Ghabkari, Abdulhameed

PY - 2014

Y1 - 2014

N2 - Aberrant DNA methylation of tumor suppressor genes has been reported in all major types of leukemia with potential involvement in the inactivation of regulatory cell cycle and apoptosis genes. However, most of the previous reports did not show the extent of concurrent methylation of multiple genes in the four leukemia types. Here, we analyzed six key genes (p14, p15, p16, p53, DAPK and TMS1) for DNA methylation using methylation specific PCR to analyze peripheral blood of 78 leukemia patients (24 CML, 25 CLL, 12 AML, and 17 ALL) and 24 healthy volunteers. In CML, methylation was detected for p15 (11%), p16 (9%), p53 (23%) and DAPK (23%), in CLL, p14 (25%), p15 (19%), p16 (12%), p53 (17%) and DAPK (36%), in AML, p14 (8%), p15 (45%), p53 (9%) and DAPK (17%) and in ALL, p15 (14%), p16 (8%), and p53 (8%). This study highlighted an essential role of DAPK methylation in chronic leukemia in contrast to p15 methylation in the acute cases, whereas TMS1 hypermethylation was absent in all cases. Furthermore, hypermethylation of multiple genes per patient was observed, with obvious selectiveness in the 9p21 chromosomal region genes (p14, p15 and p16). Interestingly, methylation of p15 increased the risk of methylation in p53, and vice versa, by five folds (p=0.03) indicating possible synergistic epigenetic disruption of different phases of the cell cycle or between the cell cycle and apoptosis. The investigation of multiple relationships between methylated genes might shed light on tumor specific inactivation of the cell cycle and apoptotic pathways.

AB - Aberrant DNA methylation of tumor suppressor genes has been reported in all major types of leukemia with potential involvement in the inactivation of regulatory cell cycle and apoptosis genes. However, most of the previous reports did not show the extent of concurrent methylation of multiple genes in the four leukemia types. Here, we analyzed six key genes (p14, p15, p16, p53, DAPK and TMS1) for DNA methylation using methylation specific PCR to analyze peripheral blood of 78 leukemia patients (24 CML, 25 CLL, 12 AML, and 17 ALL) and 24 healthy volunteers. In CML, methylation was detected for p15 (11%), p16 (9%), p53 (23%) and DAPK (23%), in CLL, p14 (25%), p15 (19%), p16 (12%), p53 (17%) and DAPK (36%), in AML, p14 (8%), p15 (45%), p53 (9%) and DAPK (17%) and in ALL, p15 (14%), p16 (8%), and p53 (8%). This study highlighted an essential role of DAPK methylation in chronic leukemia in contrast to p15 methylation in the acute cases, whereas TMS1 hypermethylation was absent in all cases. Furthermore, hypermethylation of multiple genes per patient was observed, with obvious selectiveness in the 9p21 chromosomal region genes (p14, p15 and p16). Interestingly, methylation of p15 increased the risk of methylation in p53, and vice versa, by five folds (p=0.03) indicating possible synergistic epigenetic disruption of different phases of the cell cycle or between the cell cycle and apoptosis. The investigation of multiple relationships between methylated genes might shed light on tumor specific inactivation of the cell cycle and apoptotic pathways.

KW - Acute leukemia

KW - Chronic leukemia

KW - DAPK

KW - DNA methylation

KW - p14

KW - p15

KW - p16

KW - p53

KW - TMS1

UR - http://www.scopus.com/inward/record.url?scp=84894073785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894073785&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2014.15.1.75

DO - 10.7314/APJCP.2014.15.1.75

M3 - Article

VL - 15

SP - 75

EP - 84

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 1

ER -